Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day −1 ) in the treatment of cutaneous or lymphocutaneous sporotrichosis
dc.contributor.author | Chapman, S. W. | en_US |
dc.contributor.author | Pappas, Peter G. | en_US |
dc.contributor.author | Kauffmann, C. | en_US |
dc.contributor.author | Smith, E. B. | en_US |
dc.contributor.author | Dietze, R. | en_US |
dc.contributor.author | Tiraboschi-Foss, N. | en_US |
dc.contributor.author | Restrepo, A. | en_US |
dc.contributor.author | Bustamante, A. B. | en_US |
dc.contributor.author | Opper, C. | en_US |
dc.contributor.author | Emady-Azar, S. | en_US |
dc.contributor.author | Bakshi, R. | en_US |
dc.date.accessioned | 2010-06-01T20:58:51Z | |
dc.date.available | 2010-06-01T20:58:51Z | |
dc.date.issued | 2004-02 | en_US |
dc.identifier.citation | Chapman, S. W.; Pappas, P.; Kauffmann, C.; Smith, E. B.; Dietze, R.; Tiraboschi-Foss, N.; Restrepo, A.; Bustamante, A. B.; Opper, C.; Emady-Azar, S.; Bakshi, R. (2004). "Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day −1 ) in the treatment of cutaneous or lymphocutaneous sporotrichosis." Mycoses 47(1-2): 62-68. <http://hdl.handle.net/2027.42/74074> | en_US |
dc.identifier.issn | 0933-7407 | en_US |
dc.identifier.issn | 1439-0507 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74074 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14998402&dopt=citation | en_US |
dc.format.extent | 107924 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Verlag, GmbH | en_US |
dc.rights | 2004 Blackwell Publishing Ltd | en_US |
dc.subject.other | Sporotrichosis | en_US |
dc.subject.other | Lymphocutaneous Infection | en_US |
dc.subject.other | Antimycotic Chemotherapy | en_US |
dc.subject.other | Terbinafine | en_US |
dc.subject.other | Efficacy | en_US |
dc.subject.other | Sporotrichose | en_US |
dc.subject.other | Lymphokutane Infektion | en_US |
dc.subject.other | Antimykotische Chemotherapie | en_US |
dc.subject.other | Terbinafin | en_US |
dc.subject.other | Wirksamkeit | en_US |
dc.title | Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day −1 ) in the treatment of cutaneous or lymphocutaneous sporotrichosis | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dentistry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical School and Veteran Affairs Medical Centre, Ann Arbour, MI, USA | en_US |
dc.contributor.affiliationother | University of Mississippi Medical Center, Jackson, MS, USA | en_US |
dc.contributor.affiliationother | University of Alabama, Birmingham, AL, USA | en_US |
dc.contributor.affiliationother | University of New Mexico, Albuquerque, NM, USA | en_US |
dc.contributor.affiliationother | NÚcleo de DoenÇas Infecciosas, Universidade Ferderal do Espirito Santo, Vitoria, Brazil | en_US |
dc.contributor.affiliationother | University of SÃo Paulo, RibeirÃo Preto, SÃo Paulo, Brazil | en_US |
dc.contributor.affiliationother | National University of Columbia, Medellin, Columbia | en_US |
dc.contributor.affiliationother | Instituto de Medicina Tropical ‘Alexander von Humboldt’, Universidad Peruana Cayetano Heredia, Lima, Peru | en_US |
dc.contributor.affiliationother | Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA | en_US |
dc.contributor.affiliationother | Novartis Pharma AG, Basel, Switzerland | en_US |
dc.identifier.pmid | 14998402 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74074/1/j.1439-0507.2003.00953.x.pdf | |
dc.identifier.doi | 10.1046/j.1439-0507.2003.00953.x | en_US |
dc.identifier.source | Mycoses | en_US |
dc.identifier.citedreference | Kwon-Chung KJ, Bennet JE. Sporotrichosis. In: Kwon-Chung KJ, Bennett JE ( eds ), Medical Mycology. Philadelphia: Lea & Febiger, 1992: 707 – 29. | en_US |
dc.identifier.citedreference | Hajjeh R, McDonnell S, Reef S et al. Outbreaks of sporotrichosis among tree nursery workers. J Infect Dis 1997; 176: 499 – 504. | en_US |
dc.identifier.citedreference | Chapman SW, Daniel CR. Cutaneous manifestations of fungal infection. Infect Dis Clin N Am 1994; 95: 879 – 910. | en_US |
dc.identifier.citedreference | Winn RE. Sporotrichosis. Infect Dis Clin N Am 1988; 2: 899 – 911. | en_US |
dc.identifier.citedreference | Rex JH, Bennet JE. Administration of potassium iodide to normal volunteers does not increase killing of Sporothrix schenckii by their neutrophils or monocytes. J Med Vet Mycol 1990; 28: 185 – 9. | en_US |
dc.identifier.citedreference | Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981 – 5. | en_US |
dc.identifier.citedreference | Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 684 – 7. | en_US |
dc.identifier.citedreference | Evans EGV, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. BMJ 1999; 318: 1031 – 5. | en_US |
dc.identifier.citedreference | Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353 – 7. | en_US |
dc.identifier.citedreference | Ryder NS, Leitner I. In vitro activity of terbinafine (Lamisil): an update. J Dermatol Treat 1998; 9: S23 – 8. | en_US |
dc.identifier.citedreference | Shadomy S, Espinel-Ingroff A, Gebhart RJ. In-vitro studies with SF 86–327, a new orally active allylamine derivative. Sabouradia 1985; 23: 125 – 32. | en_US |
dc.identifier.citedreference | Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126 ( Suppl. 39 ): 51 – 55. | en_US |
dc.identifier.citedreference | Forsana CV, Carrozzo V, Forte I, Peserico A. Cutaneous lymphangitic sporotrichosis treated with terbinafine. Acta Dermatol Venereol 1994; 3: 161 – 3. | en_US |
dc.identifier.citedreference | Kudoh K, Kamei E, Terunama A et al. Successful treatment of cutaneous sporotrichosis with terbinafine. J Dermatol Treat 1996; 7: 33 – 35. | en_US |
dc.identifier.citedreference | Jacyk WK, Ayerst KF, RÖscher M. Sporotrichosis. Review of sixty-five cases from South Africa. Mikol Lek 2000; 7: 189 – 96. | en_US |
dc.identifier.citedreference | Morishita N, Yamazaki K, Ninomiya J et al. A case of lymphocutaneous sporotrichosis. Nippon Ishinkin Gakkai Zasshi 2001; 42: 149 – 54. | en_US |
dc.identifier.citedreference | Morris-Jones R, Sarkany R, Hay J. Lymphocutaneous sporotrichosis. Br J Dermatol 2001; 145: 38 – 39. | en_US |
dc.identifier.citedreference | Petranyi G, Meingassner JG, Mieth H. Antifungal activity of allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365 – 8. | en_US |
dc.identifier.citedreference | Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol 1999; 141: 36 – 40. | en_US |
dc.identifier.citedreference | Perez A. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 1999; 42 ( Suppl. 2 ): 111 – 4. | en_US |
dc.identifier.citedreference | Lesher JL, Fitch MH, Dunlap DB. Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis. Cutis 1994; 53: 128 – 30. | en_US |
dc.identifier.citedreference | Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital: case 28, 1994. N Engl J Med 1994; 331: 181 – 7. | en_US |
dc.identifier.citedreference | Conti Diaz IA, Civilia E, Gezule E et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153 – 6. | en_US |
dc.identifier.citedreference | Sharkey-Mathis PK, Kauffman CA, Graybill JR et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279 – 85. | en_US |
dc.identifier.citedreference | Karakayali G, Lenk N, Ali N, Gungor E, Artuz F. Itraconazole therapy for lymphocutaneous sporotrichosis: a case report and review of the literature. Cutis 1998; 61: 106 – 7. | en_US |
dc.identifier.citedreference | Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121 – 6. | en_US |
dc.identifier.citedreference | Adel-Rhaman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997; 31: 445 – 56. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.